Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Inventory (2016 - 2026)

Aytu Biopharma has reported Inventory over the past 11 years, most recently at $8.7 million for Q4 2025.

  • Quarterly Inventory fell 21.91% to $8.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2025, down 21.91% year-over-year, with the annual reading at $11.4 million for FY2025, 5.82% down from the prior year.
  • Inventory was $8.7 million for Q4 2025 at Aytu Biopharma, down from $10.1 million in the prior quarter.
  • Over five years, Inventory peaked at $16.6 million in Q4 2021 and troughed at $8.7 million in Q4 2025.
  • The 5-year median for Inventory is $12.9 million (2022), against an average of $12.7 million.
  • Year-over-year, Inventory soared 151.98% in 2021 and then plummeted 33.6% in 2022.
  • A 5-year view of Inventory shows it stood at $16.6 million in 2021, then fell by 21.79% to $13.0 million in 2022, then increased by 0.39% to $13.0 million in 2023, then dropped by 14.74% to $11.1 million in 2024, then dropped by 21.91% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Inventory are $8.7 million (Q4 2025), $10.1 million (Q3 2025), and $11.4 million (Q2 2025).